Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

PURPOSE: Modulation of vascular endothelial growth factor–mediated immune suppression via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We report results from the dose-finding and initial phase II expansion of a phase Ib/II study of lenvatinib plus pembrolizumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Matthew H., Lee, Chung-Han, Makker, Vicky, Rasco, Drew, Dutcus, Corina E., Wu, Jane, Stepan, Daniel E., Shumaker, Robert C., Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145588/
https://www.ncbi.nlm.nih.gov/pubmed/31961766
http://dx.doi.org/10.1200/JCO.19.01598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145588/
https://www.ncbi.nlm.nih.gov/pubmed/31961766
http://dx.doi.org/10.1200/JCO.19.01598

Ejemplares similares